CD30

CD30, also known as TNFRSF8, is a cell membrane is_associated_with::protein of the is_associated_with::tumor necrosis factor receptor family and is_associated_with::tumor marker.

Function
This receptor is expressed by activated, but not by resting, T and is_associated_with::B cells. is_associated_with::TRAF2 and is_associated_with::TRAF5 can interact with this receptor, and mediate the signal transduction that leads to the activation of is_associated_with::NF-kappaB. It is a positive regulator of is_associated_with::apoptosis, and also has been shown to limit the proliferative potential of autoreactive CD8 effector T cells and protect the body against autoimmunity. Two alternatively spliced transcript variants of this gene encoding distinct isoforms have been reported.

Clinical significance
CD30 is associated with is_associated_with::anaplastic large cell lymphoma. It is expressed in is_associated_with::embryonal carcinoma but not in is_associated_with::seminoma and is thus a useful marker in distinguishing between these is_associated_with::germ cell tumors. CD30 and CD15 are also expressed on classical is_associated_with::Hodgkin Lymphoma is_associated_with::Reed-Sternberg cells.

Cancer treatment
CD30 is the target of the FDA approved therapeutic Brentuximab Vedotin (is_associated_with::Adcetris), designed and developed by Seattle Genetics. It is approved for use in:
 * 1) is_associated_with::Hodgkin lymphoma (HL) (brentuximab vedotin) after failure of autologous stem cell transplant (ASCT)
 * 2) HL in patients who are not ASCT candidates after failure of at least 2 multiagent chemotherapy regimens
 * 3) Systemic anaplastic large cell lymphoma (sis_associated_with::ALCL) after failure of at least 1 multiagent chemotherapy regimen

Interactions
CD30 has been shown to interact with is_associated_with::TRAF5, is_associated_with::TRAF1, is_associated_with::TRAF2 and is_associated_with::TRAF3.